About the Event
The diagnostic market for stress-related diseases is $60B. Inmedix has developed the first device that precisely measures stress biology based on next-generation heart rate variability (HRV) testing. It’s a proprietary SaaS platform with two recurrent revenue streams and 90% SaaS margins.
Joint our Fireside Chat to hear more about the science and why Inmedix has the potential to become a multi-unicorn from:
- Bernie Tobin, General Manager, Natera, an experienced pharma executive with leadership positions at Amgen, Lilly, and most recently Crescendo Bioscience.
- David Sun, CEO, Coaching International and an active coach. He has founded global tech firms, and served as Chief Strategy Officer or a major Family Office and PE firm.
- Andrew Holman MD, CEO, Inmedix, Dr. Holman is the Inc PS, Director of Research at Pacific Rheumatology Research Inc., and founder of Inmedix.